Due to its protective effect on the brain and the myocardium, hypothermia therapy (HT) has been extensively studied in cardiac arrest patients with coma as well as in patients presenting with acute myocardial infarction (MI). In the setting of cardiac arrest, randomized studies have shown that HT decreases mortality and improves neurological outcomes. Subsequent guidelines have therefore recommended cooling (32°C to 34°C) for 12 to 24 h in unconscious adult patients with spontaneous circulation after out-of-hospital cardiac arrest due to ventricular fibrillation. Observational studies have also confirmed the feasibility of this therapy in clinical practice and support its early application in patients with nonventricular fibrillation cardiac arrest and in post-resuscitation circulatory shock. In patients with acute MI, available clinical evidence does not yet support HT as the standard of care, because no study to date has shown a clear net benefit in such a cohort. After a brief review of the mechanisms of action for HT, we provide a review of the clinical evidence, cooling techniques, and potential adverse effects associated with HT in the setting of post-cardiac arrest patient and acute MI. (J Am Coll Cardiol 2012;59:197-210)
Mild hypothermia therapy (HT), defined as body temperature between 32°C and 35°C, has been examined in a multitude of brain injury models, such as ischemic and hemorrhagic stroke, spinal cord injury, hepatic encephalopathy, traumatic brain injury, and neonatal hypoxic-ischemic encephalopathy. Randomized clinical trials (RCTs) in the setting of cardiac arrest (1, 2) and neonatal hypoxic-ischemic encephalopathy (3) (4) (5) have in turn validated the clinical applicability of such therapy. Due to its potential myocardial protective properties, the role of HT might well extend beyond its neuroprotective properties in patients presenting with coma after a cardiac arrest to patients presenting with an acute myocardial infarction (MI).
Mechanisms of Action of Hypothermia
Neuroprotection. Experimental and clinical evidence have confirmed the neuroprotective effects of hypothermia. The mechanism(s) underlying the beneficial properties of HT are multifactorial and include reductions in the cerebral metabolism of glucose and oxygen consumption (6 -8) ; pathways mediating accumulation of excito-toxic neurotransmitters, intracellular acidosis, and the influx of intracellular calcium and oxygen free radical production (9, 10) ; alterations in the expression of "cold shock proteins" (10 -12) ; reduction in brain edema (13, 14) ; minimizing the risk of thrombosis; and reducing the risk of epileptic activities through electrical stabilizing properties (10) . Cardioprotection. A number of preclinical studies have demonstrated the beneficial effects of HT in reducing infarct size, with the greatest benefit being derived when the heart is cooled before reperfusion, thereby indicating a potential correlation between the degree of myocardial salvage and the myocardial temperature at the time of reperfusion (15) (16) (17) (18) (19) (20) (21) (22) (23) . Although the mechanisms by which HT enhances myocardial protection have not been as thoroughly elucidated as in the brain, a number of potential explanations have been proposed. These include reducing the metabolic demand of the myocardium at risk (24) , enhancing cellular membrane integrity through increased adenosine triphosphate preservation (24, 25) , enhancing mitochondrial membrane stability (26 -29) , and improvements in the myocardial microvasculature blood flow (22,30 -32) .
HT and Cardiac Arrest
Randomized controlled clinical trials. After observational clinical studies suggesting a beneficial effect for HT in survivors of cardiac arrest (33) , 2 pivotal RCTs have provided the definitive evidence for such an efficacy (Table 1) (1, 2) . In the first study (1) , HT was shown to be associated with improvements in neurological outcome and survival at 6 months in survivors of cardiac arrest due to ventricular fibrillation (VF) or pulseless ventricular tachycardia. In the second study (2) , HT initiated in the ambulance was again found to be associated with improvements in neurological outcome as compared with normothermia. A subsequent metaanalysis concluded that the numberneeded-to-treat to allow 1 additional patient to leave the hospital with improvements in neurological outcome was 6 (95% confidence interval: 4 to 13) (34) . The International Liaison Committee on Resuscitation recommended HT (32°C to 34°C for 12 to 24 h), on the basis of such results, in unconscious adult patients with spontaneous circulation after out-ofhospital cardiac arrest when the initial rhythm is VF (class IIa). Cooling was also recommended for survivors of non-VF cardiac arrest patients (class IIb) (35, 36) . These recommendations have also been incorporated in the more recently published resuscitation guidelines (37, 38) . Observational studies. The feasibility and favorable neurological outcomes associated with HT have also been confirmed in a multitude of observational studies (Table 2 ) (39 -63) . In a retrospective study of unselected comatose survivors of all rhythm cardiac arrest patients, Holzer et al. (46) demonstrated that HT was associated with better survival and improvements in neurological outcome at 1 month. The ERC HACA (European Resuscitation Council Hypothermia After Cardiac Arrest) registry of 650 comatose patients after all rhythm cardiac arrest has also confirmed that HT led to a higher discharge survival rate and improvements in neurological outcome (40) . Similarly, the Hypothermia Network Registry of 986 all rhythm cardiac arrest patients also confirmed the clinical efficacy of HT in this cohort of patients (51) . HT in non-VF cardiac arrest. Although the feasibility of HT in non-VF cardiac arrest patients has been confirmed (53, 64) , no study to date has shown either a survival or a neurological benefit with HT in this cohort of patients (62, 65) . One potential reason for this observation might be the poor prognosis associated with asystole, regardless of the therapeutic measure undertaken (66) . HT in post-resuscitation circulatory shock. Animal data have suggested a beneficial effect of HT in cardiogenic shock mediated through modulations in inflammation, apoptosis, and remodeling (67, 68) . In humans, although post-resuscitation shock is a relatively frequent complication of cardiac arrest (66) , such patients have been excluded from RCTs, and the results of observational studies have been hampered by variations used to define "shock" and lack of report on outcomes in this subset of patients (Table 2) . In 2 retrospective studies focusing on patients presenting with post-resuscitation shock, HT did not adversely affect the expected outcome (47, 61) . HT and emergency coronary intervention. Several observational studies have shown that combining HT with immediate coronary angiography Ϯ percutaneous coronary intervention (PCI) is feasible and might improve the outcome of comatose patients who have been successfully resuscitated from cardiac arrest due to ST-segment elevation myocardial infarction (STEMI) (49, 55, 58, 59) . In 1 of the earliest studies to address this combination, Sunde et al. (58) showed an improvement in neurological outcomes and survival at discharge after implementation of a standardized post-resuscitation care protocol including HT. In a prospective study with historical control that included 72 comatose patients successfully resuscitated from VF related to STEMI and who needed primary PCI, Knafelj et al. (49) reported greater 6-month survival and improvements in neurological outcomes in patients receiving HT without adversely affecting the symptom-to-balloon time. Other studies have also demonstrated that implementing such a strategy does not adversely influence the door-to-balloon time (59) .
HT and Acute MI
Animal models of MI have suggested that HT might be an effective method in reducing infarct size (15, 17, 69, 70) . In humans, several studies have examined HT as a novel method to reduce myocardial injury in patients with STEMI (Table 3) (72, 77) were designed to address whether or not HT could decrease infarct size as measured by single-photon emission computed tomography imaging at 30 days in the STEMI population. However, neither study demonstrated such a benefit-although in patients presenting with anterior STEMI and who had achieved a core temperature Ͻ35°C, a favorable trend was observed. Furthermore, a sub-analysis of the ERC HACA trial (78) failed to show any significant impact of HT on such parameters as creatine kinase, creatine kinase myocardial-band, or electrocardiogram evaluation. Interestingly, patients in the HT group with a shorter time to target temperature (Յ8 h) had significantly reduced levels of creatine kinase and creatine kinase myocardial-band, suggesting that early cooling rather than its duration might be a critical factor in achieving infarct size reduction (15, 17, 22, 23, 69, 70) .
Both experimental and clinical studies seem to suggest that, in addition to early cooling, the optimal cardioprotective effects of hypothermia might be derived at core temperatures Ͻ35°C (15, 22, 23, 72, 77) . Such a hypothesis has received additional support from Götberg et al. (76) , who demonstrated, in patients undergoing primary PCI for STEMI, not only that a core body core temperature of Ͻ35°C could be achieved without delaying the door-toballoon time but that it was also associated with a 38% 18 device-related adverse events: Nasal discoloration: n ϭ 13 Epistaxis: n ϭ 3 Peri-oral bleeding:
n ϭ 1 Peri-orbital emphysema: n ϭ 1 *Favorable neurological outcome was defined by a Cerebral Performance Categories scale of 1 (good recovery) or 2 (moderate disability) in the HACA (Hypothermia After Cardiac Arrest) study, by discharge home or to a rehabilitation facility in the Bernard et al. (2) study, and by the neurologically intact survival for the PRINCE (Pre-ROSC IntraNasal Cooling Effectiveness) trial. C ϭ control subjects; CI ϭ confidence interval; CPR ϭ cardiopulmonary resuscitation; H ϭ hypothermia; m ϭ months; MI ϭ myocardial infarction; OR ϭ odds ratio; PEA ϭ pulseless electrical activity; ROSC ϭ recuperation of spontaneous circulation; temp ϭ temperature; VF ϭ ventricular fibrillation; VT ϭ ventricular tachycardia. Asys ϭ asystole; ECD ϭ endovascular cooling device; ExC ϭ external cooling device; HR ϭ hazard ratio; IABP ϭ intra-aortic balloon pump; IG ϭ intervention group; MAP ϭ mean arterial pressure; PPCI ϭ primary percutaneous coronary intervention; SBP ϭ systolic blood pressure; other abbreviations as in Table 1 .
Nonrandomized Clinical Studies of Hypothermia Therapy in Cardiac Arrest
reduction in the infarct size as assessed by cardiac magnetic resonance imaging (CMRI). Although relatively small in sample size, this was the first such study demonstrating a beneficial effect of HT in this population. The achievement of a body core temperature Ͻ35°C and the use of CMRI, currently the "gold-standard" for infarct assessment (79) (80) (81) , have been proposed as potential explanations for the observed benefits. In contrast to single-photon emission computed tomography, which has been used in the majority of the aforementioned studies, CMRI has the advantage that it provides information not only on geometrical information such as ventricular volume but also segmental wall motion abnormalities and left ventricular function as well as remodeling.
However, despite such encouraging results, the optimal method and timing of HT in the STEMI population would No difference AUC ϭ area under the curve; cath ϭ catheterization; CHF ϭ cardiac heart failure; CK ϭ creatinine kinase; LV ϭ left ventricle; MACE ϭ major adverse cardiac event(s); RCT ϭ randomized control trial; SPECT ϭ single-photon emission computed tomography; TVR ϭ target vessel revascularization; other abbreviations as in Tables 1 and 2. 204 Delhaye et al.
require an adequately powered RCT, and until such data become available, the utility of HT will remain conjectural and cannot be recommended in routine, daily clinical practice for this cohort of patients.
Cooling Techniques
The currently available cooling methods have been largely developed in the setting of post-cardiac arrest comatose survivors and are detailed in the following text (82) (83) (84) (85) (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) (96) .
Cold infusion. The infusion of cold fluid has been shown to be an effective technique to cool patients, especially for the induction phase, rendering it a readily accessible strategy in an out-of-hospital environment. Different protocols have been proposed, such as the infusion of 30 ml/kg of ice-cold (4°C) lactated Ringers solution intravenously over 30 min (83) or the use of 500 to 2,000 ml of 4°C normal saline as soon as possible after resuscitation (84) . The latter protocol has been validated in an RCT showing that cold infusion initiated in the field is effective in lowering arrival hospital temperature without adverse consequences in terms of blood pressure, heart rate, arterial oxygenation, risk of pulmonary edema or re-arrest (84) . Although the cold fluid intravenous infusion seemed to be effective, safe, and quick to induce HT, it does not seem sufficient to be used alone for the maintenance phase of HT and needs the additional use of either external cooling techniques or endovascular cooling devices (85, 86) . External cooling techniques. External cooling therapy is a simple, inexpensive, easy-to-implement technique achieved with the application of ice packs to the groin, torso, axillae, and neck and/or ice water-soaked towels and fanning. This method can be considered for both the induction and maintenance phases in the intensive care unit but suffers from the inability to control the rate of de-cooling as well as the extreme vigilance and experience required to prevent over-cooling (87) . A number of commercially available cooling devices are now available, including cooling mattresses, air-filled or water circulating cooling blankets, and garment-type surface cooling devices (88) . In addition to a tight thermoregulatory capacity, these devices have the distinct advantage of reducing the risk of over-cooling during the induction phase, but they are expensive and associated with rare adverse skin reactions (skin erythema and mottling underneath the cooling pads) (89) . Non-cold infusion endovascular cooling techniques. Initially developed to cool non-intubated awake patients, to decrease cold discomfort and shivering, this method has been used in the post-cardiac arrest setting over the last few years (71, 75) . The endovascular cooling method consists of an endovascular cooling catheter that is commonly inserted percutaneously into the inferior vena cava and connected to an automatically guided temperature cooling system. This system extracts heat directly from the core and is not impaired by thermoregulatory skin vasoconstriction (90) . As a consequence, the device allows the rapid and accurate establishment of the target temperature, is effective in maintaining a stable temperature after induction, and allows an efficient control of the re-warming phase (60, (91) (92) (93) 
Establishment of HT
The establishment of HT can be divided into 3 steps: induction, maintenance, and re-warming phase (Fig. 1) .
Complications of HT and Its Management
Hypothermia therapy is associated with a number of common physiological changes and potential complications (Table 4 ) (10, 88) . Shivering. Shivering is a natural physiological response to hypothermia and can impede both the induction and maintenance phases of HT by generating heat and increasing the oxygen consumption and metabolic demands of tissues (97) . After peripheral vasoconstriction, shivering seems to be the "last resort" response against cold as the core temperature falls below 35.5°C. Numerous pharmacological strategies have been developed to counteract such a response (90) . In the post-cardiac arrest setting, a widely adopted combination is that of benzodiazepines for sedation, opioid analgesic, and systemic neuromuscular blockade for muscle relaxation (2) . By contrast, the combination of meperidine (Ϯ buspirone) and skin warming to reduce the shivering threshold and avoid 205 JACC Vol. 59, No. 3, 2012 Delhaye et al.
thermal discomfort has become the standard of care in awake patients (71,74 -77) . Cardiovascular manifestations of HT. The cardiovascular effects of hypothermia are complex and have been summarized in Table 4 (10, 88) . After the induction phase, HT might be accompanied by bradycardia and an increase in myocardial contractility (88, 98) . This reduction in heart rate might in turn give rise to a reduction in cardiac output, although this is not sufficiently severe enough to lead to hemodynamic compromise (10, 88) . At this stage, the hypothermia-induced vasoconstriction of peripheral arteries and arterioles might increase the systemic vascular resistance and lead to a slight increase in the arterial pressure (88, 99, 100) . However, cardiac arrest patients who have been cooled also develop a hypotensive response as a consequence of the "post-cardiac arrest syndrome," which is characterized by myocardial dysfunction, a systemic ischemia-reperfusion response, as well as a systemic inflammatory response (66) . Furthermore, such a hypotensive response might be further exacerbated by the underlying cause of cardiac arrest, such as MI, ventricular arrhythmia, and the "cold diuresis" that can accompany HT through several mechanisms, such as increased venous return due to peripheral vasoconstriction, misbalance in diuretic hormones, and tubular dysfunction (10) . Although HT has not been associated with the development of arrhythmia in RCTs or in observational studies, persistent arrhythmia can develop as a consequence of over-cooling (Յ32°), electrolyte imbalance, or tubular dysfunction (10).
Infection. Although HT might increase the rate of infection as a consequence of hypothermia-induced impairment of cellular and humoral immunity (101), the message from clinical studies does not provide a uniform answer as to whether this hypothetical risk is of clinical significance. Several studies have indicated an increased clinical risk (46, 59) , whereas others have refuted such findings (53, 58, 102) . Bleeding. Hypothermia might result in an increased risk of bleeding as a result of impaired platelet function, thrombopenia, and impairment of the coagulation cascade (88) . However, such risks have not been observed in clinical practice when HT has been used in isolation or in combination with PCI. Alterations in drug metabolism. Hypothermia leads to a slowing of a number of hepatic enzymes including the cytochrome P450. Therefore, drugs that are metabolized by the liver, such as sedative and neuromuscular blocking agents, will require dose modification (103) .
Conclusions
Hypothermia therapy should be considered, on the basis of current evidence, as the standard of care in post-cardiac arrest patients irrespective of the initial rhythm as recommended by the guidelines. However, many unanswered questions remain, such as the optimal duration of hypothermia, depth of cooling, rate of re-warming, best cooling method, and cost effectiveness. In patients presenting with Adjust infusion rates, use preferentially bolus dose rather than increasing infusion dose Adapted, with permission, from Polderman et al. (10, 83) . ECG ϭ electrocardiographic; HR ϭ heart rate; HT ϭ hypothermia therapy.
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